Dr. David Samadi, the Chairman of Urology who is also the Chief of Robotic Surgery at Lenox Hill Hospital, commented on Mitt Romney’s, the Former Republican presidential nominee, prostate cancer. Dr. Thomas Ahlering performed the surgery last summer on Mitt Romney to remove the prostate gland that was growing slowly. The operation took place at UC Irvine Hospital in California. Some believe that Mitt Romney is planning to run for the U.S. Senate seat in Utah.
Mitt Romney, one of the 161,360 men who had prostate cancer in 2017, recovered completely from the surgery. Mitt Romney joins many politicians who were fortunate enough to recover from prostate cancer, to name a few, Colin Powell, the former Secretary of State, John Kerry, the 2002 Presidential candidate.
Dr. David Samadi, a graduate of ‘S.U.N.Y. Stony Brook School of Medicine and completed an oncology fellowship at ‘Memorial Sloan Kettering Cancer Center’ majoring in proctology, discussed the choices that Mitt Romney had to treat his prostate cancer. Dr. Samadi, a board-certified urologic oncologist, recommends surgery over radiation as the preferred treatment especially if cancer did not spread beyond the prostate gland. Dr. David Samadi cited few studies that showed that removal of the prostate gland is more effective in this situation than radiation.
His reasons for recommending surgery of radiation are:
- treating with radiation causes twice as much death in men who have prostate cancer than men who opted for surgery.
- treating men with radiation can lead to secondary cancer in the bladder or rectum. if cancer comes back after radiation treatment, treatment in the form of surgery will not be an option.
- When the patient is treated with radiation and later on discovers cancer spread to other organs outside the prostate, his survival rate will be much lower, about 30% and the patient may not live more than five years.
- Removing the prostate through surgery have been proven to improve survival rate to 100%.
Dr. David Samadi, one of the most experienced robotic prostate surgeons in the world, recommends that men diagnosed with prostate cancer to find a qualified, experienced urologist/oncologist to educate them to make an informed decision to defeat cancer.
Dr. David Samadi specializes in the use of robotic surgery in the treatments of prostate cancer. In his practice, he strives to treat the patient as a whole and take them through the hardship of the disease to safe future and cancer free.
Over 14 million people in the United States will contract some form of cancer during their lifetimes. With the rising population, that number will inevitably rise drastically. However, with new technological advances being made by people like Eric Lefkofsky, who co-founded Tempus, future patients may have a more hopeful outlook.
Tempus has created technology that will streamline the care of cancer patients by maintaining and analyzing their individual medical and clinical data. The software also includes voice recognition technology that will convert spoken word into structured data that can then be analyzed to afford the best care for individual patient. When this information is combined with genome information, doctors will be able to pair patients with the best treatment options. Using this system will also allow the information to be updated in real time. For more info about us: http://chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/ click here.
After he graduated from the University of Michigan in Ann Arbor in 1993 with a law degree, Lefkofsky got swept up by the early dot com boom and became one of the key players in that arena. He founded a number of successful Internet businesses, the most well-known being Groupon. He invested $1 million in Groupon after hearing about the idea from a former boss, Andrew Mason.
Along with his wife, Elizabeth, Lefkofsky founded the charitable trust, the Lefkofsky Foundation, which focuses on giving funds to organizations that help children. To date, the foundation as given aid to more than 50 different charities.
After his wife was diagnosed with breast cancer, Lefkofsky noticed that cancer treatment and research seemed to be behind the times. He aimed to do something about it, and hopefully to change the way cancer patients are treated using data collection and digital technology. After overcoming a few hurdles along the way, it looks as if Tempus may be doing just that.
Cancer and other related diseases have done so much havoc on many lives that most people find it difficult imagining a world free of these ailments. These folks should not be castigated for this, they and their loved ones may have seen and passed through horrible times in battle this monster called cancer, but there are now some reasons to be positive. Time and space will not permit me to dive into all the reasons. However, I will try and do some justice to one – the unrelenting effort of Dr Mikhail Blagosklonny against cancer and aging.
Mikhail Blagosklonny has always had one goal, rescuing men and women including the young and old from the shackles of cancer and aging. He submitted himself to training by fulfilling all necessary requirements for the award of an MD in Internal Medicine at the prestigious First Pavlov State Medical University of St. Petersburg. He was not done with just an MD. He studied further and earned a PhD in a PhD from the same University. Visit classroomvoices.org to read more about Mikhail.
He wanted working experience in some of the most equipped organizations in the world in terms of human know-how and up-to-date technologically advanced medical facilities. This took him to work in places such as New York Medical College as an associate professor, Ordway Research Institute as a senior scientist, and Roswell Park Cancer Institute as a professor of Oncology to date.
If cancer could speak like humans, it will single out Mikhail Blagosklonny as one of the fiercest enemies. He has carried out hundreds of researches all in the bid to discover more effective targeted cancer therapies. This dynamic man came up with a hypothesis called TOR signaling which has proven very helpful in combating cancer and aging. The world will always remember him for this. He is also a strong advocate of rapamycin as an effective drug for cancer since it helps to retard the growth of tumors and by extension the aging process.
With the likes of Mikhail Blagosklonny, the devastation done by cancer and aging on humans will soon be a thing of the past, so it is not out of place to start thinking of a cancer-free world. Read more on templeofthecave.com
Seattle Genetics has been continuing its projects with the largest funding possible. The company has increased its $480 million public stock offering to $552 million. They did this because of the over-allotment option.
Seattle Genetics has been able to increase the stock amounts because of the large amounts of interest offered from investors. In addition to using the funds for drug pipeline and expanding the use of its flagship cancer drug Adcetris, Seattle Genetics will continue to bring in more employees and expand their work environment. The company is planning on hiring at least one hundred new employees every year over the course of the next five years. That would mean the company would have to make room for over 1200 employees by 2020.
Seattle Genetics is looking at other buildings to lease near Canyon Park area of Bothell. The company is located at 21823 30th Dr. S.E. The company is working on pushing growth as fast as possible. There have been no promises yet, but there are expected to be more buildings under their name in the new future.
Seattle Genetics was founded in 1998. The have now grown to be one of the largest biotech companies. However, they are not at the stage where they can earn much profit. The company has made a good amount of profit from selling Adcetris, but all the medical equipment and research costed the company a lot of money. CEO of the company, Siegall, has said that the lack of profit thus far has nothing to do with future growth. There is still so much to build.
It is common for biotech companies to to take a long time before earning any significant profit. Seattle Genetics is continuing their research to find all possible uses for Adcetris beyond cancer. They will continue to advance drugs through their pipeline.
Clay Siegall is the president of Seattle Genetics. He earned his Bachelor of Science in Zoology at the University of Maryland and a Doctor of Philosophy. He helped grow the company until it became an industry leader. Siegall has multiple licenses with affiliated companies such as ADC technology, including with Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer. He has earned $675 million through public and private funding.